Earnings Call · Q4 FY2023·2024-02-07

Q4 23EPS +1.99%·Rev n/aQ3 23EPS +15.79%·Rev n/aQ2 23EPS +11.61%·Rev n/aQ1 23EPS -100.00%*·Rev n/a⚠ consensus missing

NEUROCRINE BIOSCIENCES INC NBIX

Todd Tushla — Investor Relations or similar (inferred from context)

Kevin Gorman — Chief Executive Officer

Matt Abernethy — Chief Financial Officer

Eric Benevich — Chief Commercial Officer

Eiry Roberts — Chief Medical Officer

−4.7%1d on move date−5.5% vs SPY3d−7.5%5d−6.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NBIX calls or request research access.

More NBIX calls Browse calls Request research access